Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibody drug aims to restore skin color in vitiligo patients

NCT ID NCT07223229

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times

Summary

This study tests a new drug called EI-001 in 45 adults with nonsegmental vitiligo, a condition that causes white patches on the skin. The drug works by calming the immune system to reduce inflammation that leads to pigment loss. Participants will receive either EI-001 or a placebo to see if it safely improves skin color over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Linkou Chang Gung Memorial Hospital

    RECRUITING

    Taoyuan, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Skin Care Research, LLC

    NOT_YET_RECRUITING

    Hollywood, Florida, 33021, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • U Mass Chan Medical School

    WITHDRAWN

    Worcester, Massachusetts, 01605, United States

Conditions

Explore the condition pages connected to this study.